Partnership to investigate Lysosomal Modulators

摘要

The Medicines Discovery Institute,Cardiff University(MDI)and Astex Pharmaceuticals,a Cambridge-based developer of small molecule therapeutics for oncology and diseases of the central nervous system,are working together to identify new drugs to treat neurodegenerative diseases with high unmet medical need.The research will build on the world-leading research expertise of Dr Emyr Lloyd-Evans & Dr Helen Waller-Evans in lysosomal biology,the drug discovery capabilities of the MDI and the fragment-based drug discovery platform at Astex using a chosen target with the aim to identify and optimise compounds that modulate lysosomal activity.Lysosomes are a subset of organelles crucial for cellular function and mutations in the genes encoding lysosomal and associated proteins are linked to a number of neurodegenerative and lysosomal storage diseases for which there are currently no effective treatments.